Transrektal Prostat İğne Biyopsisinin Erektil Fonksiyon Üzerine Etkisi

Amaç: Transrektal ultrasonografi eşliğinde prostat biyopsi işleminin, hastalarıncinsel fonksiyonu üzerine olan etkilerini, işlem öncesinde ve sonrasındafarklı zaman aralıkları ile değerlendirmek. Hastalar ve yöntem: Çalışmayaişlem öncesi Uluslararası Prostat Semptom Skoru (IPSS) ve UluslararasıErektil İşlev Formu (IIEF-5) doldurtulan ve işlem sonrası bu formlar tekrar 1.ve 3. aylarda doldurtulmuş olan ve biyopsi sonucu prostat kanseri ile uyumlugelmeyen 80 hasta alındı. IIEF-5’e göre hastaların erektil fonksiyonları 5 kategoriyeayrıldı; 5-7: ağır erektil disfonksiyon (ED), 8-11: orta ED, 12-16: hafif-orta ED, 17-21: hafif ED, 22-25: ED olmayan. Bulgular: Hastaların %45’i (36/80) üç günden fazla süren rektal kanama şikayeti bildirdiler. Üç gündenuzun süren hematospermi ve/veya hematüri şikayeti hastaların %78,8’inde (63/80) gözlemlendi. Biyopsi öncesi IIEF skor ortalaması 24.3±8.4 idi.Biyopsi sonrası 1. ve 3. aylardaki IIEF skor ortalamaları sırası ile 20.3±9,6 ve22.4±8.9 idi (p

The Impact of Transrectal Prostate Needle Biopsies on Erectile Functions

Object: To evaluate the effects of transrectal ultrasound guided biopsies of the prostate on patients’ sexual function at different time intervals (before and after the procedure). Material and methods: Eighty prostate cancer free patients were included the study, those were completed the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) before, and 1 and 3 mounths after biopsy. We classified erectile function into five categories according to IIEF-5 scores: severe (5–7), moderate (8–11), mild-moderate (12–16), mild (17-21) and no ED (22–25). Results: 45% (36/80) of the patients notified rectal bleeding complaints continuing for over three days. Hematospermia and /or hematuria complaints that prolonged over three days were observed at 78.8% (63/80) of patients . The mean IIEF score before biopsy was 24.3 ± 8.4. The mean IIEF score at the first and third months after biopsy was 20.3 ± 9.6 and 22.4 ± 8.9, respectively (p

PDF

___

Murray KS, Bailey J, Zuk K, Lopez-Corona E, Thrasher JB. A prospective study of erectile function after transrectal ultrasonography-guided prostate biopsy. BJU Int. 2015 Aug;116(2):190-5.
Chrisofos M, Papatsoris AG, Dellis A, Varkarakis IM, Skolarikos A, Deliveliotis C. Can prostate biopsies affect erectile function? Andrologia 2006;38:79–83.
van den Bergh RC, Korfage IJ, Roobol MJ, Bangma CH, de Koning HJ, Steyerberg EW, et al. Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU Int 2012;110:1032-9.
Hilton JF, Blaschko SD, Whitson JM, Cowan JE, Carroll PR. The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol 2012;188:1252-8.
Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009; 182: 2664-9.
Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety and erectile dysfunction. J Urol 2001;165(2):445-54.
Verrier RL, Dickerson LW. Autonomic nervous system and coronary blood flow changes related to emotional activation and sleep. Circulation 1991;83:1181- 1189.
Feldman HA, Goldstein I, Hatzichristou D, Krane RJ, McKinlay JB. Impotence and its medical and psychological correlates: Results of the Massachusets Male Ageing Study. J Urol 1994;151:54-61.
Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, McNicholas TA. Prevalence of undiagnosed prostate cancer in men with erectile dysfunction. BJU Int 2002; 89: 261-3.
Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin NA 1995;22:699-709.
Manoharan M, Ayyathurai R, Nieder AM, Soloway MS. Hemospermia following transrectal ultrasound- guided prostate biopsy: a prospective study. Prostate Cancer Prostatic Dis 2007;10:283–7.
Namekawa T, Fukasawa S, Komaru A, Kobayashi M, Imamura Y, Ohzeki T et al. Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events. Int J Clin Oncol 2015;20:1185–91.
Berger AP, Gozzi C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004;171:1478–80.
Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound- guided sextant biopsies of the prostate within a population-based screening program. Urology 2002;60:826–30.
Roberts MJ, Williamson DA, Hadway P, Doi SA, Gardiner RA, Paterson DL. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis. Int J Antimicrob Agents 2014;43:301-9.
Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 2014;192:1673-8.
Bruyere F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet JD et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol 2015;193:145–50.
Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol 2014;192:1116–22.
Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001 Sep;166(3):856-60.
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830–4.
Loeb S, Vellekoop A, Ahmed HU,Catto J, Emberton M, Nam R et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876–92.